Wecare's New Mega Plant: Revolutionizing China's Probiotic Industry with Cutting-Edge Innovation

The recent commissioning of Wecare's Phase III probiotic strain factory, boasting a remarkable production capacity of 600 tons, signifies a quantum leap in the company's production capabilities and scale of probiotic strains.

Probiotic strains form the very foundation of the probiotic industry. To achieve international quality leadership and sustainable growth in probiotic manufacturing, mastering the research, production, and application of "strain chips" is essential.

Recently, the commissioning of Wecare's Phase III probiotic strain factory, with a production capacity of 600 tons, marks a significant leap in Wecare's production capability and scale of probiotic strains.

The total investment in the Wecare Phase III probiotic strain factory project has reached CNY 1.5 billion, with over CNY 500 million allocated for research and development and CNY 1 billion for intelligent manufacturing production lines. The new construction area spans 100,000 square meters, making it the largest probiotic strain research and intelligent manufacturing base in Asia. With the commissioning of the Phase III factory, Wecare has achieved an annual production target of nearly 1,000 tons of probiotic powder, accounting for over 90% of the domestic production capacity. Currently, the company has developed into the largest in Asia and a global leader in probiotic raw materials, with products exported to more than 80 countries and regions in the Americas, Europe, and Australia.

Located in the Wujiang Development Zone, Wecare Probiotics is a national high-tech enterprise in China focused on the research, production, and application of probiotic strains grounded in microbiomes. The company has a specialized probiotic research institute, academician workstations, and postdoctoral research stations, with a dedicated research team of over 150 people, constituting more than 20% of the workforce, and an annual research investment ratio exceeding 15%. The company also operates a 4,000-square-meter high-standard professional probiotic strain testing center. Currently, Wecare has established a probiotic strain resource library with over 30,000 strains, applied for more than 300 invention patents, and received authorization for over 140.

Wecare has planned and built five world-class probiotic strain intelligent manufacturing bases, three of which are already completed. With the commissioning of the Phase III project, large-scale production and new processes have directly reduced the cost of probiotic powders by over 50%. Additionally, two other bases are under construction, including the Phase IV 1,200-ton probiotic powder factory and the Phase V 1,000-ton Bacillus coagulans factory, scheduled to commence production by the end of 2024. Upon completion of the Phase IV and Phase V factories, the company's total production capacity will reach 2,000 tons of probiotic strain powder and 1,000 tons of Bacillus coagulans powder.